James Ford

Publications

• The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. Lin PS, McPherson LA, Chen AY, Sage J, Ford JM. DNA Repair (Amst). 2009; 8 (7): 795-802
• Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Cancer Res. 2009; 69 (8): 3589-96
• Second primary breast cancer occurrence according to hormone receptor status. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. J Natl Cancer Inst. 2009; 101 (15): 1058-65
• Performance of BRCA1/2 mutation prediction models in Asian Americans. Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM. J Clin Oncol. 2008; 26 (29): 4752-8
• Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cisco RM, Ford JM, Norton JA. Cancer. 2008; 113 (7 Suppl): 1850-6
• CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. Ann Surg. 2007; 245 (6): 873-9
• Predicting and preventing hereditary colorectal cancer. Ford JM, Whittemore AS. JAMA. 2006; 296 (12): 1521-3
• Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. Bomgarden RD, Lupardus PJ, Soni DV, Yee MC, Ford JM, Cimprich KA. EMBO J. 2006; 25 (11): 2605-14
• Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. Ji H, Kumm J, Zhang M, Farnam K, Salari K, Faham M, Ford JM, Davis RW. Cancer Res. 2006; 66 (16): 7910-9
• A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Chen X, Zhang J, Lee J, Lin PS, Ford JM, Zheng N, Zhou P. Mol Cell. 2006; 22 (4): 489-99
• Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, Ford JM, Plevritis SK. Cancer. 2004; 100 (3): 479-89
• p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Fitch ME, Cross IV, Ford JM. Carcinogenesis. 2003; 24 (5): 843-50
• The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. Fitch ME, Cross IV, Turner SJ, Adimoolam S, Lin CX, Williams KG, Ford JM. DNA Repair (Amst). 2003; 2 (7): 819-26
• In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. Fitch ME, Nakajima S, Yasui A, Ford JM. J Biol Chem. 2003; 278 (47): 46906-10
• p53 and regulation of DNA damage recognition during nucleotide excision repair. Adimoolam S, Ford JM. DNA Repair (Amst). 2003; 2 (9): 947-54
• p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Adimoolam S, Ford JM. Proc Natl Acad Sci U S A. 2002; 99 (20): 12985-90
• BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Hartman AR, Ford JM. Nat Genet. 2002; 32 (1): 180-4
• Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. Tang JY, Hwang BJ, Ford JM, Hanawalt PC, Chu G. Mol Cell. 2000; 5 (4): 737-44
• Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Proc Natl Acad Sci U S A. 1999; 96 (2): 424-8
• Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. Ford JM, Hanawalt PC. J Biol Chem. 1997; 272 (44): 28073-80
• Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Ford JM, Hanawalt PC. Proc Natl Acad Sci U S A. 1995; 92 (19): 8876-80
• A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FC, Chan SW, Ying MW, Ma ES, Ford JM. Breast Cancer Res Treat. 2009; 117 (3): 683-6
• Pathological Response after Chemoradiation for T3 Rectal Cancer. Chennupati SK, Kamaya A, Fisher GA, Ford JM, Kunz P, Itakura H, Welton ML, Shelton A, Van Dam J, Koong AC, Chang DT. Colorectal Dis. 2009
• Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Cancer. 2009; 115 (3): 665-72
• Detection of solitary humeral metastasis from pancreatic adenocarcinoma with F-18 FDG PET/CT. Kim J, Quon A, Humke E, Ford JM, Koong AC. Clin Nucl Med. 2009; 34 (5): 312-3
• Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology. Kurian AW, Hartman AR, Mills MA, Logan LJ, Sawyer AM, Ford JM, Daniel BL. Breast J. 2008 Mar-Apr; 14 (2): 211-4
• Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Kingham K, Chun N, Ford JM, Longacre TA. Am J Surg Pathol. 2008; 32 (6): 799-809
• Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC. Int J Radiat Oncol Biol Phys. 2008; 72 (3): 678-86
• Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM. Fam Cancer. 2008; 7 (2): 179-86
• Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Kwong A, Wong LP, Chan KY, Ma ES, Khoo US, Ford JM. Fam Cancer. 2008; 7 (2): 125-33
• Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Schiffman JD, Chun N, Fisher PG, Dahl GV, Ford JM, Eggerding FA. Pediatr Blood Cancer. 2008; 50 (4): 914-6
• Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Jensen KC, Mariappan MR, Putcha GV, Husain A, Chun N, Ford JM, Schrijver I, Longacre TA. Am J Surg Pathol. 2008; 32 (7): 1029-37
• Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. Ghanouni P, Kurian AW, Margolis D, Hartman AR, Mills MA, Plevritis SK, Ford JM, Daniel BL. Breast J. 2007 May-Jun; 13 (3): 281-6
• A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K, Ford JM. Cancer Genet Cytogenet. 2007; 179 (2): 89-92
• Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Mullins FM, Dietz L, Lay M, Zehnder JL, Ford J, Chun N, Schrijver I. Genet Med. 2007; 9 (11): 752-60
• Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. JAMA. 2007; 297 (21): 2360-72
• Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Alli E, Yang JM, Ford JM, Hait WN. Mol Pharmacol. 2007; 71 (5): 1233-40
• HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. Proc Natl Acad Sci U S A. 2007; 104 (49): 19482-7
• Colorectal Cancer Screening Clinical Practice Guidelines. Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin EW, Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ. J Natl Compr Canc Netw. 2006; 4 (4): 384-420
• Genetic/familial high-risk assessment: breast and ovarian. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. J Natl Compr Canc Netw. 2006; 4 (2): 156-76
• Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Park JG, Kim DW, Hong CW, Nam BH, Shin YK, Hong SH, Kim IJ, Lim SB, Aronson M, Bisgaard ML, Brown GJ, Burn J, Chow E, Conrad P, Douglas F, Dunlop M, Ford J, Greenblatt MS, Heikki J, Heinimann K, Lynch EL, Macrae F, McKinnon WC, Möeslein G, Rossi BM, Rozen P, Schofield L, Vaccaro C, Vasen H, Velthuizen M, Viel A, Wijnen J. Clin Cancer Res. 2006; 12 (11 Pt 1): 3389-93
• Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Cancer Epidemiol Biomarkers Prev. 2005; 14 (5): 1082-9
• Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Ford JM, Mutat Res. 2005; 577 (1-2): 195-202
• Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Kurian AW, Hartman AR, Mills MA, Ford JM, Daniel BL, Plevritis SK. Health Expect. 2005; 8 (3): 221-33
• Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Clin Cancer Res. 2005; 11 (15): 5401-9
• Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Int J Radiat Oncol Biol Phys. 2005; 63 (2): 320-3
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. J Clin Oncol. 2005; 23 (24): 5613-9
• Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA. Int J Radiat Oncol Biol Phys. 2004; 58 (4): 1017-21
• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G. Int J Radiat Oncol Biol Phys. 2003; 55 (1): 132-7
• Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Proc Natl Acad Sci U S A. 2003; 100 (17): 9974-9
• BRCA1 and p53: compensatory roles in DNA repair. Hartman AR, Ford JM. J Mol Med. 2003; 81 (11): 700-7
• Functional characterization of global genomic DNA repair and its implications for cancer. Hanawalt PC, Ford JM, Lloyd DR. Mutat Res. 2003; 544 (2-3): 107-14
• Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, Niederhuber J, Bastidas JA. J Gastrointest Surg. 2001 Jan-Feb; 5 (1): 27-35
• Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ. Arch Surg. 2001; 136 (1): 65-9
• Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, Young H, Fisher G. Dis Colon Rectum. 2001; 44 (1): 52-8
• The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. Adimoolam S, Lin CX, Ford JM. J Biol Chem. 2001; 276 (28): 25813-22
• Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Fisher GA. Am J Clin Oncol. 2001; 24 (2): 155-9
• Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Poen JC. Int J Radiat Oncol Biol Phys. 2000; 48 (5): 1483-7
• Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. Lopez CD, Ao Y, Rohde LH, Perez TD, O'Connor DJ, Lu X, Ford JM, Naumovski L. Mol Cell Biol. 2000; 20 (21): 8018-25
• Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. Bowman KK, Sicard DM, Ford JM, Hanawalt PC. Mol Carcinog. 2000; 29 (1): 17-24
• Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice. Ichikawa M, Nakane H, Marra G, Corti C, Jiricny J, Fitch M, Ford JM, Ikejima M, Shimada T, Yoshino M, Takeuchi S, Nakatsu Y, Tanaka K. Mutat Res. 2000; 459 (4): 285-98
• p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace AJ. Mol Cell Biol. 2000; 20 (10): 3705-14
• Chemoradiotherapy in the management of localized tumors of the pancreas. Poen JC, Ford JM, Niederhuber JE. Ann Surg Oncol. 1999 Jan-Feb; 6 (1): 117-22
• Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Ford JM, Baron EL, Hanawalt PC. Cancer Res. 1998; 58 (4): 599-603
• Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. Prost S, Ford JM, Taylor C, Doig J, Harrison DJ. J Biol Chem. 1998; 273 (50): 33327-32
• Role of DNA excision repair gene defects in the etiology of cancer. Ford JM, Hanawalt PC. Curr Top Microbiol Immunol. 1997: 221 47-70
• P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Ford JM, Yang JM, Hait WN. Cancer Treat Res. 1996: 87 3-38
• Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Ford JM, Eur J Cancer. 1996; 32A (6): 991-1001
• Modulators of multidrug resistance. Preclinical studies. Ford JM, Hematol Oncol Clin North Am. 1995; 9 (2): 337-61
• Preferential repair of ultraviolet light-induced DNA damage in the transcribed strand of the human p53 gene. Ford JM, Lommel L, Hanawalt PC. Mol Carcinog. 1994; 10 (2): 105-9
• Pharmacologic circumvention of multidrug resistance. Ford JM, Hait WN. Cytotechnology. 1993; 12 (1-3): 171-212
• Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Ford JM, Hait WN, Matlin SA, Benz CC. Cancer Lett. 1991; 56 (1): 85-94
• Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Ford JM, Yang JM, Hait WN. Cancer Res. 1991; 51 (1): 67-72
• Pharmacology of drugs that alter multidrug resistance in cancer. Ford JM, Hait WN. Pharmacol Rev. 1990; 42 (3): 155-99
• Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cancer Res. 1990; 50 (6): 1748-56
• Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH. Mol Pharmacol. 1990; 37 (6): 840-7
• Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ. J Clin Oncol. 1989; 7 (9): 1359-64
• Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Ford JM, Prozialeck WC, Hait WN. Mol Pharmacol. 1989; 35 (1): 105-15